These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12118026)

  • 1. Modulation of irinotecan metabolism by ketoconazole.
    Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
    J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
    Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
    Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
    Sai K; Kaniwa N; Ozawa S; Sawada JI
    Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
    Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of phenytoin on the disposition of irinotecan: a case report.
    Murry DJ; Cherrick I; Salama V; Berg S; Bernstein M; Kuttesch N; Blaney SM
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):130-3. PubMed ID: 11990699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
    van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
    Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
    Haaz MC; Riché C; Rivory LP; Robert J
    Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
    Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
    Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
    van der Bol JM; Mathijssen RH; Creemers GJ; Planting AS; Loos WJ; Wiemer EA; Friberg LE; Verweij J; Sparreboom A; de Jong FA
    Clin Cancer Res; 2010 Jan; 16(2):736-42. PubMed ID: 20068078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
    d'Esposito F; Nebot N; Edwards RJ; Murray M
    Br J Clin Pharmacol; 2010 Sep; 70(3):400-8. PubMed ID: 20716241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
    de Jong FA; Kitzen JJ; de Bruijn P; Verweij J; Loos WJ
    Cancer Biol Ther; 2006 Sep; 5(9):1105-10. PubMed ID: 16969123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
    Charasson V; Haaz MC; Robert J
    Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
    Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
    Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
    Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
    Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
    Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
    Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of St. John's wort on irinotecan metabolism.
    Mathijssen RH; Verweij J; de Bruijn P; Loos WJ; Sparreboom A
    J Natl Cancer Inst; 2002 Aug; 94(16):1247-9. PubMed ID: 12189228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.